Research · Dossier
Retatrutide
As of Jun 7 · 2,354 reports · 1,446 authors
A
Effective
weight
B
Safety
monitor HR
01SnapshotMechanism
Triple hormone receptor agonist acting as a GLP-1, GIP & glucagon agonist. Investigated for obesity and type-2 diabetes, where it lowers body weight and HbA1c.
02Real-world cohortHigh confidence
Across 2,354 classified reports from 1,446 people, the most-reported real-world effect is weight loss. Community signal — not a clinical outcome.
1,258 personal-use · 53% 410 speculative · 17% 686 third-party · 29%
Sentiment · 1,258 personal-usemean +0.26
51% positive 29% neutral 20% adverse
03What people experience
Effects
weight loss 447 appetite suppression 179 reduced food noise 40 muscle retention 21
Side-effects
fatigue 43 nausea 36 low libido 17
04How people use itDose · route
Reported doses · median 4 mg/wk · P10–P90 2–8 mg
2 mg 0.5–7.5 · n=449 4 mg/wk 1–12 · n=88 8 mg/wk 2–6 · n=23
05Vs your stackGrounded
Caution2 interactions · 2 safe
Delays gastric emptying — may alter absorption kinetics of oral Adderall at your 60 mg dose. No material interaction with NAD, Melanotan-2 or Epitalon.
Checked against your stack (4): Adderall · NAD · Melanotan-2 · Epitalon

The whole compound, graded.

RESEARCH · COHORT, DOSES & STACK INTERACTIONS